Wills MR - Search Results

1

Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention.

Groves IJ, Jackson SE, Poole EL, Nachshon A, Rozman B, Schwartz M, Prinjha RK, Tough DF, Sinclair JH, Wills MR. Groves IJ, et al. Among authors: wills mr. Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):e2023025118. doi: 10.1073/pnas.2023025118. Proc Natl Acad Sci U S A. 2021. PMID: 33619107 Free PMC article.

2

Latency and reactivation of human cytomegalovirus.

Sissons JG, Bain M, Wills MR. Sissons JG, et al. Among authors: wills mr. J Infect. 2002 Feb;44(2):73-7. doi: 10.1053/jinf.2001.0948. J Infect. 2002. PMID: 12076064 Review.

3

Human cytomegalovirus and immunopathology.

Sissons JG, Carmichael AJ, McKinney N, Sinclair JH, Wills MR. Sissons JG, et al. Among authors: wills mr. Springer Semin Immunopathol. 2002;24(2):169-85. doi: 10.1007/s00281-002-0104-0. Springer Semin Immunopathol. 2002. PMID: 12503063 Review. No abstract available.

4

Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation.

Gandhi MK, Wills MR, Sissons JG, Carmichael AJ. Gandhi MK, et al. Among authors: wills mr. Blood Rev. 2003 Dec;17(4):259-64. doi: 10.1016/s0268-960x(03)00028-6. Blood Rev. 2003. PMID: 14556781 Review.

5

Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis.

Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, Wilkinson GW, Sinclair J, Sissons JG. Wills MR, et al. J Immunol. 2005 Dec 1;175(11):7457-65. doi: 10.4049/jimmunol.175.11.7457. J Immunol. 2005. PMID: 16301653

6

Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.

Thomas M, Boname JM, Field S, Nejentsev S, Salio M, Cerundolo V, Wills M, Lehner PJ. Thomas M, et al. Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1656-61. doi: 10.1073/pnas.0707883105. Epub 2008 Jan 29. Proc Natl Acad Sci U S A. 2008. PMID: 18230726 Free PMC article.

7

Human cytomegalovirus immunity and immune evasion.

Jackson SE, Mason GM, Wills MR. Jackson SE, et al. Among authors: wills mr. Virus Res. 2011 May;157(2):151-60. doi: 10.1016/j.virusres.2010.10.031. Epub 2010 Nov 5. Virus Res. 2011. PMID: 21056604 Review.

8

The co-speciation of human cytomegalovirus (HCMV) with its human host has enabled this human pathogen to evolve multiple mechanisms to allow it to be carried, generally sub-clinically, for the lifetime of the host in the face of a robust immune response. Preface.

Wills M, Sinclair J. Wills M, et al. Virus Res. 2011 May;157(2):127. doi: 10.1016/j.virusres.2010.11.002. Epub 2010 Nov 13. Virus Res. 2011. PMID: 21078350 No abstract available.

9

A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity.

Kuan WL, Poole E, Fletcher M, Karniely S, Tyers P, Wills M, Barker RA, Sinclair JH. Kuan WL, et al. J Exp Med. 2012 Jan 16;209(1):1-10. doi: 10.1084/jem.20111126. Epub 2011 Dec 19. J Exp Med. 2012. PMID: 22184634 Free PMC article.

10

Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model.

Huang MM, Kew VG, Jestice K, Wills MR, Reeves MB. Huang MM, et al. Among authors: wills mr. J Virol. 2012 Aug;86(16):8507-15. doi: 10.1128/JVI.00598-12. Epub 2012 May 30. J Virol. 2012. PMID: 22647696 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

298 results

Search Page